Literature DB >> 8851566

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

E J Arts1, M A Wainberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851566      PMCID: PMC163153     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  181 in total

1.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.

Authors:  W A O'Brien; A Namazi; H Kalhor; S H Mao; J A Zack; I S Chen
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

Authors:  E L White; W B Parker; L J Macy; S C Shaddix; G McCaleb; J A Secrist; R Vince; W M Shannon
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

Review 3.  Mutagenesis and deoxyribonucleotide pool imbalance.

Authors:  B A Kunz
Journal:  Mutat Res       Date:  1988 Jul-Aug       Impact factor: 2.433

4.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis.

Authors:  V Bianchi; E Pontis; P Reichard
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

6.  3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation.

Authors:  R W Buckheit; J Germany-Decker; K Qualls-Goodwin; B J Bowdon; W M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

7.  The effects of dNTP pool imbalances on frameshift fidelity during DNA replication.

Authors:  K Bebenek; J D Roberts; T A Kunkel
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

8.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 9.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

10.  Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.

Authors:  S F Lacey; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more
  22 in total

Review 1.  Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Authors:  Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 3.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.

Authors:  J J McSharry; N S Lurain; G L Drusano; A L Landay; M Notka; M R O'Gorman; A Weinberg; H M Shapiro; P S Reichelderfer; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.

Authors:  R A Smith; K M Remington; B D Preston; R F Schinazi; T W North
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  A photolabile 2',3'-dideoxyuridylate analog bearing an aryl(trifluoromethyl)diazirine moiety: photoaffinity labeling of HIV-1 reverse transcriptase.

Authors:  T Yamaguchi; M Saneyoshi
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

9.  Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Authors:  S J Hurwitz; B C Tennant; B E Korba; J L Gerin; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.

Authors:  Yong Gao; Ellen Paxinos; Justin Galovich; Ryan Troyer; Heather Baird; Measho Abreha; Cissy Kityo; Peter Mugyenyi; Christos Petropoulos; Eric J Arts
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.